Table 2

Multivariate linear regression models assessing the association between patient’s characteristics and quantitative humoral and cellular response

	ED50 alpha		ED50 delta		SARS-CoV-2-specific IFNγ-producing T cells
	β coefficient(95% CI)	P value	β coefficient(95% CI)	P value	β coefficient(95% CI)	P value
Age, years	7.49 (−25.17 to 40.14)	0.649	2.16 (−1.91 to 6.22)	0.294	−1.61 (−4.41 to 1.18)	0.253
Treatment group controls	Ref		Ref		Ref	Ref
Immunosupressants	−1809.56 (−3590.36 to to 28.77)	0.047	−434.85 (−669.67 to 200.03)	<0.001	26.40 (−126.56 to 179.35)	0.731
Methotrexate	−2729.50 (−4485.78 to 973.23)	0.003	−462.83 (−701.35 to 224.31)	<0.001	−70.95 (−227.87 to 85.97)	0.370
Rituximab	−3153.98 (−4823.90 to 1484.06)	<0.001	−583.41 (−803.88 to 362.95)	<0.001	77.73 (−62.81 218.26)	0.273
Other	−398.73 (−2351.02 1553.55)	0.685	−190.32 (−440.08 59.43)	0.133	−35.00 (−198.04 to 128.04)	0.669
Glucocorticoids (%)	−50.01 (−1332.51, 1232.50)	0.938	−48.87 (−207.06 to 109.31)	0.540	−44.34 (−153.91 to 65.23)	0.4222
IgA, g/L	31.61 (−279.05 to 342.27)	0.840	0.10 (−41.14 to 41.34)	0.996	45.96 (14.67 to 77.25)	0.005
IgG2, g/L	189.43 (−183.08 to 561.95)	0.314	246.59 (−29.18 to 522.36)	0.079	−11.57 (−38.53 to 15.38)	0.394